MESOTHELIOMA

This early-phase study tests an oral drug called IAG933 in adults with advanced mesothelioma and certain other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 13…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo …

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests a new radiation technique called IMRT for people with malignant pleural mesothelioma, a rare lung cancer. The goal is to see if combining surgery, chemotherapy, and this targeted radiation is safe and reduces severe lung side effects. About 65 adults with early-s…

This study tests whether using a special breathing device (AEROBIKA) after chest surgery can help prevent lung collapse (atelectasis) in people with lung cancer, mediastinal tumors, or mesothelioma. About 72 participants will be randomly assigned to either standard rehab therapy …

This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the trial was withdraw…

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This study tests a treatment using a patient's own immune cells (T cells) that are genetically modified to recognize and attack a protein called mesothelin found on cancer cells. The treatment is given through a tube in the chest to people with malignant pleural disease, includin…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study tests a new support program for adults with lung cancer or mesothelioma who have finished treatment. The goal is to help them improve their quality of life as they move from active treatment to regular check-ups. About 21 participants will try the program to see if it …

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This research study collects blood, tumor tissue, and other body fluids from 1,000 adults with lung cancer, thymus cancer, or mesothelioma. The goal is to analyze these samples to find biological markers that could predict how the disease will progress or which treatments might w…